178 related articles for article (PubMed ID: 11827989)
1. Tumor immunotherapy: inching toward the finish line.
Curiel TJ; Curiel DT
J Clin Invest; 2002 Feb; 109(3):311-2. PubMed ID: 11827989
[No Abstract] [Full Text] [Related]
2. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy with mRNA-transfected dendritic cells.
Gilboa E; Vieweg J
Immunol Rev; 2004 Jun; 199():251-63. PubMed ID: 15233739
[TBL] [Abstract][Full Text] [Related]
4. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
[TBL] [Abstract][Full Text] [Related]
5. [mRNA-transfected dendritic cells: a promising strategy in immunotherapy].
Maisnier-Patin K; Crabé S; Breton G; Dupuy FP; Yassine-Diab B; Sékaly RP
Med Sci (Paris); 2007 Mar; 23(3):279-84. PubMed ID: 17349289
[TBL] [Abstract][Full Text] [Related]
6. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
8. Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.
Le Gallo M; Toutirais O; Montier T; Cabillic F; Bouet F; Delépine P; Lehn P; Jotereau F; Catros V
J Gene Med; 2008 Jun; 10(6):628-36. PubMed ID: 18338820
[TBL] [Abstract][Full Text] [Related]
9. [RNA-loaded dendritic cells].
Hinoda Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():613-8. PubMed ID: 15861719
[No Abstract] [Full Text] [Related]
10. Dendritic cells pick up the pace in trials.
Veggeberg S
Mol Med Today; 1997 Dec; 3(12):518-9. PubMed ID: 9449120
[No Abstract] [Full Text] [Related]
11. The immunotherapy of prostate and bladder cancer.
Totterman TH; Loskog A; Essand M
BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of prostate cancer.
Doehn C
Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
[No Abstract] [Full Text] [Related]
14. Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.
Mincheff M; Zoubak S; Altankova I; Tchakarov S; Pogribnyy P; Makogonenko Y; Botev C; Meryman HT
Cancer Gene Ther; 2005 Feb; 12(2):185-97. PubMed ID: 15375382
[TBL] [Abstract][Full Text] [Related]
15. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
16. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
Kalady MF; Onaitis MW; Padilla KM; Emani S; Tyler DS; Pruitt SK
J Surg Res; 2002 Jun; 105(1):17-24. PubMed ID: 12069496
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and functional differences of dendritic cells generated under different in vitro conditions.
McArdle SE; Ali SA; Li G; Mian S; Rees RC
Methods Mol Med; 2003; 81():359-75. PubMed ID: 12725131
[No Abstract] [Full Text] [Related]
18. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
19. [Cell therapy in solid tumors].
Ravaud A
Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
[No Abstract] [Full Text] [Related]
20. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
Van Meirvenne S; Dullaers M; Heirman C; Straetman L; Michiels A; Thielemans K
Mol Ther; 2005 Nov; 12(5):922-32. PubMed ID: 16257383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
